Terms: = Bone cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Prognosis
12 results:
1. Regulatory function and mechanism research for m6A modification WTAP via SUCLG2-AS1- miR-17-5p-jak1 axis in AML.
Liu M; Yu B; Tian Y; Li F
BMC Cancer; 2024 Jan; 24(1):98. PubMed ID: 38233760
[TBL] [Abstract] [Full Text] [Related]
2. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/jak1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract] [Full Text] [Related]
3. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Moyo TK; Mendler JH; Itzykson R; Kishtagari A; Solary E; Seegmiller AC; Gerds AT; Ayers GD; Dezern AE; Nazha A; Valent P; van de Loosdrecht AA; Onida F; Pleyer L; Cirici BX; Tibes R; Geissler K; Komrokji RS; Zhang J; Germing U; Steensma DP; Wiseman DH; Pfeilstöecker M; Elena C; Cross NCP; Kiladjian JJ; Luebbert M; Mesa RA; Montalban-Bravo G; Sanz GF; Platzbecker U; Patnaik MM; Padron E; Santini V; Fenaux P; Savona MR;
BMC Cancer; 2022 Sep; 22(1):1013. PubMed ID: 36153475
[TBL] [Abstract] [Full Text] [Related]
4. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.
Villaume MT; Arrate MP; Ramsey HE; Sunthankar KI; Jenkins MT; Moyo TK; Smith BN; Fischer MA; Childress MA; Gorska AE; Ferrell PB; Savona MR
Exp Hematol; 2021 May; 97():57-65.e5. PubMed ID: 33617893
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.
Masarova L; Bose P; Pemmaraju N; Daver NG; Zhou L; Pierce S; Sasaki K; Kantarjian HM; Estrov Z; Verstovsek S
Cancer; 2020 Oct; 126(19):4322-4331. PubMed ID: 32697338
[TBL] [Abstract] [Full Text] [Related]
6. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
[TBL] [Abstract] [Full Text] [Related]
7. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
[TBL] [Abstract] [Full Text] [Related]
8. MicroRNA-126 Inhibits Proliferation, Migration, Invasion, and EMT in Osteosarcoma by Targeting ZEB1.
Jiang R; Zhang C; Liu G; Gu R; Wu H
J Cell Biochem; 2017 Nov; 118(11):3765-3774. PubMed ID: 28379605
[TBL] [Abstract] [Full Text] [Related]
9. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract] [Full Text] [Related]
10. Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms.
Tamari R; Castro-Malaspina H
Curr Opin Hematol; 2015 Mar; 22(2):184-90. PubMed ID: 25635756
[TBL] [Abstract] [Full Text] [Related]
11. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms.
Pozdnyakova O; Hasserjian RP; Verstovsek S; Orazi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):253-61. PubMed ID: 25515354
[TBL] [Abstract] [Full Text] [Related]
12. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Gregory SA; Mesa RA; Hoffman R; Shammo JM
Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
[TBL] [Abstract] [Full Text] [Related]
